Compare GIS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | DGX |
|---|---|---|
| Founded | 1866 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9B | 20.5B |
| IPO Year | N/A | 1996 |
| Metric | GIS | DGX |
|---|---|---|
| Price | $44.24 | $182.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $53.27 | ★ $196.69 |
| AVG Volume (30 Days) | ★ 8.2M | 969.4K |
| Earning Date | 03-18-2026 | 02-10-2026 |
| Dividend Yield | ★ 5.46% | 1.74% |
| EPS Growth | 0.65 | ★ 14.49 |
| EPS | 4.63 | ★ 8.51 |
| Revenue | ★ $18,776,700,000.00 | $10,850,000,000.00 |
| Revenue This Year | N/A | $12.37 |
| Revenue Next Year | N/A | $3.54 |
| P/E Ratio | ★ $9.66 | $21.64 |
| Revenue Growth | N/A | ★ 13.74 |
| 52 Week Low | $42.79 | $153.99 |
| 52 Week High | $67.35 | $197.55 |
| Indicator | GIS | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 50.77 |
| Support Level | $44.29 | $179.73 |
| Resistance Level | $44.88 | $184.39 |
| Average True Range (ATR) | 0.98 | 3.73 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 48.25 | 48.58 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.